mdm-2 Expression correlates with wild-type p53 status in esophageal adenocarcinoma

Modern Pathology

Volumn 12, Issue 6, 1999, Pages 580-586

  Soslow, Robert A ^a,c   Altorki, Nasser K ^a   Yang, Guang Yu ^b   Xie, Dawen ^b   Yang, Chung S ^b  

^a Department of Obstetrics Gynecology   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c WMC   (United States)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; mdm 2; p53

Indexed keywords

PROTEIN P53; REGULATOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; ESOPHAGUS CARCINOMA; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; METAPLASIA; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033068065     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
3. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
4. Momand J, Zambetti GP, Olson DC, George DL, Vogelstein B. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
5. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silberman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with mdm-2 and neutralizes mdm-2's inhibition of p53. Cell 1998;92:713-23.
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
7. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 mutation and mdm-2 amplification in human soft tissue sarcomas. Cancer Res 1993;53(10 Suppl):2231-4.
8. Barak Y, Oren M. Enhanced binding of a 95-kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J 1992;11:2115-21.
9. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990;87:7555-9.
10. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
11. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand polymorphism analysis. Cancer Res 1991;51:3056-8.
12. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994;35:764-8.
13. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993;105:1637-42.
14. Hamelin R, Flejou J-F, Muzeau F, Potet F, Laurent-Puig P, Fekete F, et al. Tp53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
15. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991;51: 5482-6.
16. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995; 55:3406-11.
17. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
18. Soslow RA, Shen P U-F, Chung MH, Isacson C. Distinctive p53 and mdm-2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998;17: 129-34.
19. Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. mdm-2 gene amplification in human breast cancer. Eur J Cancer 1994;30A:982-4.
20. Esteve A, Lehman T, Jiang W, Weinstein IB, Harris CC, Ruol A, et al. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm-2 amplification in human esophageal carcinomas. Mol Carcinog 1993;8:306-11.
21. Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. In: Atlas of tumor pathology. 3rd series. Fasc 18. Washington, DC: Armed Forces Institute of Pathology; 1995.
22. Remmele W, Schicketanz K-H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Path Res Pract 1993; 189:862-6.
23. Gao H, Wang LD, Zhou W, Hong JY, Huang TY, Yang CS. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994;54:4342-6.
24. Shi ST, Feng B, Yang GY, Wang LD, Yang CS. Immunohistoselective sequencing (IHSS) of p53 tumor suppressor gene in human esophageal precancerous lesions. Carcinogenesis 1996;17:2131-6.
25. Biernat W, Kliehues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of mdm-2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1997;56:180-5.
26. Landers JE, Haines DS, Strauss JF III, George DL. Enhanced translation: a novel mechanism of mdm-2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9: 2745-50.
27. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983;3:2143-50.
28. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large-cell lymphoma. Am J Pathol 1993;143:845-9.
29. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
30. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
31. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
32. Gulley ML, Burton MP, Allred DC, Nicholls JM, Amin MB, Ro JY, et al. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum Pathol 1998;29:252-9.
33. Barak Y, Juven T, Haffner R, Oren M. mdm-2 expression is induced by wild-type p53 activity. EMBO J 1993;12:461-8.
34. Toh Y, Kuwano H, Tanaka S, Baba K, Matsuda H, Sugimachi K, et al. Detection of human papillomavirus DNA in esophageal carcinoma in Japan by polymerase chain reaction. Cancer 1992;70:2234-8.
35. Mori M, Watanabe M, Tanaka S, Mimori K, Kuwano H, Sugimachi K. Epstein-Barr virus-associated carcinomas of the esophagus and stomach. Arch Pathol Lab Med 1994;118: 998-1001.
36. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13:301-6.
37. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
38. Ambros RA, Sheehan CE, Kallakury BVS, Rose JS, Malfetano J, Paunovich E, et al. mdm-2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996;9:1165-9.
39. Selivanova G, Wiman KG. p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 1995;66:143-80.
40. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54: 794-9.
41. Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K, Kobayashi M. Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol 1996;26:287-92.
42. Casson AG, Kerkvliet N, O'Malley F. Prognostic value of the p53 protein in esophageal adenocarcinoma. J Surg Oncol 1995;60:5-11.
43. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79:425-32.
44. Gorgoulis VG, Rassidakis GZ, Karameris AM, Papastamatiou H, Trigidou R, Veslemes M, et al. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma. Mod Pathol 1996;9:544-54.